GSK to Acquire Nuvalent for $10.6B, Securing Two Potential Best-in-Class Oncology Candidates; J&J Buys Firefly Bio for $1B to Advance DAC Platform

$10.6 Billion! GSK Secures Two Potential “Best-in-Class” Anti-Cancer Small Molecules Poised for Launch This Year

Today,GSK Announces Agreement to Acquire Clinical-Stage Biopharmaceutical Company Nuvalent for $10.6 BillionNuvalent is focused on developing precision-targeted oncology therapies.The transaction includes three products in the lung cancer field at once,including two next-generation, highly selective ROS1 and ALK inhibitors, zidesamtinib (NVL-520) and neladalkib (NVL-655), which are in late-stage development and have the potential to become “best-in-class” therapies, as well as NVL-330, a HER2 inhibitor currently in Phase 1 clinical trials for HER2-altered non-small cell lung cancer (NSCLC).The transaction also includes multiple preclinical programs established by Nuvalent based on its precision medicine capabilities and clinical insights.

Zidesamtinib and neladalkib have both received FDA Breakthrough Therapy Designation and Orphan Drug Designation, and are currently under review by the U.S. FDA.The target review decision dates are September 18, 2026, and November 27, 2026, respectively.GSK stated that this acquisition will accelerate its expansion into the lung cancer field and provide a further development platform for Ris-Rez, its B7-H3-targeting antibody-drug conjugate (ADC) currently in Phase 3 clinical development. Previously announced key data indicated that zidesamtinib and neladalkib demonstrate potential “best-in-class” characteristics, including high target selectivity, durable treatment responses, improved tolerability, enhanced blood-brain barrier penetration, and broader coverage of ALK and ROS1 mutations. These attributes are expected to help patients achieve longer periods of effective treatment and better quality of life.

Johnson & Johnson Acquires Antibody-Drug Conjugate for $1 BillionProtein DegradantsXinrui

Johnson & Johnson recently announced that it has reached a final agreement to acquire biotechnology company Firefly Bio for $1 billion. Firefly Bio is advancing its proprietary Firelink antibody-drug conjugate protein degrader (DAC) platform.According to the announcement, the platform focuses on KRAS-driven tumors, with the potential to further strengthen Johnson & Johnson’s oncology pipeline and support its strategic goal of developing targeted therapies for high-incidence, refractory solid tumors with significant unmet medical needs.

Antibody therapies have profoundly transformed the landscape of cancer treatment through continuous innovation, ranging from monoclonal antibodies to bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), and other antibody-based drug formats. The Firelink DAC platform represents an innovative approach: by delivering highly selective protein degraders specifically to tumor cells while minimizing impact on healthy cells, it aims to overcome the limitations of existing therapeutic modalities. This acquisition also underscores Johnson & Johnson’s sustained focus on the potential of next-generation antibody drugs and protein degradation technologies in oncology.

$2.3 Billion! Roche Strikes Deal on BTK-Targeted Protein Degradation Agent

Nurix Therapeutics recently announced a global collaboration with Roche to co-develop and commercialize the potential “best-in-class” investigational oral BTK-targeted protein degrader, bexobrutideg.This collaboration will combine Nurix’s R&D expertise in the field of targeted protein degradation with Roche’s mature portfolio of B-cell-targeted therapies and its global clinical and commercial infrastructure.The two parties plan to launch a comprehensive clinical development program spanning malignant hematologic tumors, immunology, and neurology to explore the clinical potential of BTK degradation in different patient populations.In addition to advancing the previously disclosed pivotal Phase 2 and Phase 3 clinical trials for chronic lymphocytic leukemia (CLL), the collaboration also plans to conduct studies supporting indication expansion across various malignant hematologic oncology indications, including monotherapy and combination regimens, and will extend the development scope to immune-mediated diseases, including initiating Phase 2 clinical trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU). According to the terms of the agreement,Nurix will receive a $700 million upfront payment and is eligible for development, regulatory, and other milestone payments, with potential total payments reaching up to $2.3 billion.

Bexobrutideg is an investigational, orally administered, blood-brain barrier-penetrant, and highly selective small-molecule BTK-targeted protein degrader.BTK is a core signaling node regulating B-cell growth, development, and immune activity. Unlike traditional BTK inhibitors that block BTK kinase activity, bexobrutideg leverages the body’s natural protein clearance system—the ubiquitin-proteasome pathway—to selectively degrade BTK protein within cells, thereby simultaneously eliminating both its kinase activity and scaffolding signaling functions. Based on this catalytic degradation mechanism, the drug holds promise for delivering multiple potential advantages,including activity against wild-type BTK and mutant forms of BTK that may limit the efficacy of existing BTK inhibitors, and exert sustained pharmacodynamic effects at lower drug concentrations.